XML 23 R13.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Goodwill and Other Intangible Assets | 6 Months Ended
--- | ---
Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets The changes in the net carrying amount of goodwill for the six months ended June 30, 2018 are as follows:
Balance as of December 31, 2017 | $ | 401,954 |
Foreign currency translation | (850 | )
Balance as of June 30, 2018 | $ | 401,104 |
Assets and liabilities of acquired businesses are recorded at their estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. Other intangible assets consist of the following:
| June 30, 2018 |  | December 31, 2017
| Weighted Average Amortization Period (Years) | Gross Carrying Amount |  | Accumulated Amortization |  | Gross Carrying Amount |  | Accumulated Amortization
Amortized intangible assets: |  |  |  |  |  |  |  |
Customer and distributor relationships | 29 | $ | 214,616 |  |  | $ | (91,634 | ) |  | $ | 214,685 |  |  | $ | (86,137 | )
Promotional, marketing and distribution rights | 25 | 149,376 |  |  | (39,000 | ) |  | 149,376 |  |  | (36,000 | )
Patents and other intangible assets | 14 | 70,031 |  |  | (43,177 | ) |  | 69,668 |  |  | (42,127 | )
Developed technology | 16 | 88,132 |  |  | (4,992 | ) |  | 62,283 |  |  | (3,352 | )
Unamortized intangible assets: |  |  |  |  |  |  |  |  |  |  |  |
Trademarks and tradenames |  | 86,544 |  |  | — |  |  | 86,544 |  |  | — |
| 24 | $ | 608,699 |  |  | $ | (178,803 | ) |  | $ | 582,556 |  |  | $ | (167,616 | )
Customer and distributor relationships, trademarks and tradenames, developed technology and patents and other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. Promotional, marketing and distribution rights represent intangible assets created under our Sports Medicine Joint Development and Distribution Agreement (the "JDDA") with Musculoskeletal Transplant Foundation (“MTF”). Amortization expense related to intangible assets which are subject to amortization totaled $5.7 million and $5.2 million in the three months ended June 30, 2018 and 2017, respectively, and $11.2 million and $10.3 million in the six months ended June 30, 2018 and 2017, respectively, and is included as a reduction of revenue (for amortization related to our promotional, marketing and distribution rights) and in selling and administrative expense (for all other intangible assets) in the consolidated condensed statements of comprehensive income. Included in developed technology is $25.8 million of earn-out consideration that is considered probable as of June 30, 2018 associated with a prior asset acquisition. This is recorded in other current liabilities at June 30, 2018. This acquired developed technology has a weighted average useful life of 14 years. Included in patents and other intangible assets at June 30, 2018 and December 31, 2017 is an in-process research and development asset that is not currently amortized. The estimated intangible asset amortization expense remaining for the year ending December 31, 2018 and for each of the five succeeding years is as follows:
| Amortization included in expense |  | Amortization recorded as a reduction of revenue |  | Total
Remaining, 2018 | $ | 8,946 |  |  | $ | 3,000 |  |  | $ | 11,946 |
2019 | 18,550 |  |  | 6,000 |  |  | 24,550 |
2020 | 18,567 |  |  | 6,000 |  |  | 24,567 |
2021 | 17,614 |  |  | 6,000 |  |  | 23,614 |
2022 | 16,139 |  |  | 6,000 |  |  | 22,139 |
2023 | 15,504 |  |  | 6,000 |  |  | 21,504 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration